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ABSTRACT
In this study the LCx assay (a nucleic acid amplification assay) for Chlamydia trachomatis in
endocervical samples was compared with the Gen-Probe PACE2 assay (a nucleic acid probe assay)
for endocervical samples, and with endocervical culture. In addition, the efficacy of the LCx assay
was determined for midstream clean-catch urine samples because it is often necessary to obtain
such a sample for routine urine culture and it is simpler to collect only a single sample without also
collecting a first-void urine for LCx. Endocervical specimens from 205 patients were tested for C.
trachomatis via LCx and PACE2. Of these patients, 203 were tested by culture. Midstream clean-
catch urine samples from 75 of these patients were tested by LCx. The sensitivities and specificities
for these assays, after discrepant analysis, were 100 and 98.9% for LCx of endocervical samples,
52.4 and 100% for PACE2; and 71.4 and 100% for culture. The sensitivity/specificity of LCx for
midstream clean-catch urines was 66.7/98.5%. The apparent prevalence of C. trachomatis in our
population was 10.2%. These data indicate that among the methods tested, LCx of endocervical
samples had the highest sensitivity for C. trachomatis in this population. The senstivity of the urine
LCx assay using midstream clean-catch collected urines was considerably less than that reported
in other studies that used first-void urines but was higher than that of PACE2. Infect. Dis. Obstet.
Gynecol. 8:112-115, 2000. (C) 2000 Wiley-Liss, Inc.
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hslamydia
trachomatis (Ct) is the most common
exually transmitted bacterial infection in the
United States with an incidence of about 4-5% in
the young adult population. 1,z It causes asymptom-
atic infections in as many as 25% of men3,4 and in
75% of women,s which leads to many undetected
cases. It also leads to significant morbidity, giving a
relative risk of ectopic pregnancy of 2.4-7.96 and
causing epididymitis in approximately 3% of in-
fected males.7 These characteristics, and the fact
that this disease is readily treatable make it an ex-
cellent candidate for a screening program. There
are a variety of available methods with which to
screen for Ct including culture, the Gen-Probe
PACE2 assay (a nucleic acid probe assay), and
more recently, LCx. The LCx assay which is based
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on the ligase chain reactions is expected to have
high sensitivity since it is a nucleic acid amplifica-
tion assay, and to have high specificity because it
involves the use of four probes. In addition, LCx is
suitable for use with male and female urine
samples whereas PACE2 and culture are not. In
this study the diagnostic efficiency of the LCx as-
say was compared with that of the PACE2 assay
and with culture, and the effects on LCx of sub-
stituting midstream clean-catch urine samples for
first-void samples was evaluated.
METHODS
Study Population
Specimens were collected for Ct testing at the Her-
mann Ob/Gyn Clinic of the University of Texas
Health Science Center in Houston, Texas. The
mean age of the patients was 24.3 years with a
range of 15-49 years. Approximately 90% of these
patients were undergoing prenatal evaluation.
Most of the remainder were seen for routine check-
ups.
Specimen Collection
In all, 216 specimens were obtained; one specimen
for each type of assay was collected from each pa-
tient. Nine specimens were eliminated from the
study because of use of the wrong swab for LCx
collection. Two specimens were eliminated due to
lack of Gen-Probe and culture results. Specimens
for LCx, PACE2, and culture were collected simul-
taneously from each patient. LCx and PACE2 col-
lection of endocervical samples was according to
manufacturer’s instructions. Cervical samples for
Ct culture were collected by use of Dacron poly-
ester-tipped swabs with polystyrene handles
(Hardwood Products, Guilford, ME) and placed in
transport medium (Multi-Microbe Media, Micro
Test Inc. Lilburn, CA). Midstream clean-catch
urine samples that showed evidence of leukocytes
by urine dipstick were tested for Ct by LCx. All
patients were evaluated for pyuria by testing mid-
stream clean-catch urine samples for leukocyte es-
terase using urine dipsticks. Urine samples that
showed evidence of pyuria were sent for routine
urine culture and we obtained aliquots of those
samples for the LCx assay.
Diagnostic Tests
Specimens were tested for Ct by use of the Abbott
LCx assay (Abbott Laboratories) the PACE2 assay
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(Gen-Probe Inc. San Diego, CA), and by culture.
Ct culture9 was performed by inoculation of speci-
mens onto McCoy cell monolayers (Intracel Inc.,
Issaquah, WA) in shell vials with detection by IFA
using Micro Trak Culture Confirmation Reagent
(Syva Co., Palo Alto, CA) according to the manu-
facturer’s recommendations. Our costs per test, in-
cluding labor, were $7 for LCx, $11 for Gen-Probe,
and $13 for culture.
Discrepant Analysis
Samples positive for Ct by LCx and culture were
considered true positives. Samples positive by LCx
and negative by culture were retested by LCx at
Abbott Laboratories. Samples that were negative
by LCx at Abbott were considered false positives.
Samples that were positive by LCx at Abbott were
retested at Abbott by a ligase chain reaction assay
for the major outer membrane protein gene of Ct
(MOMP LCR) and were considered positive or
negative based on this result.
Samples found positive by culture were consid-
ered true positives. Samples found negative by cul-
ture that were true positives for LCx were consid-
ered culture false negatives. Negative PACE2
samples that were considered true positives by
LCx or culture were considered PACE2 false nega-
tives. No samples were PACE2 positive, LCx
negative.
RESULTS
A total of 205 patients were evaluated for the pres-
ence of Ct via endocervical swab by use ofLCx and
PACE2. Twenty-three cervical samples were posi-
tive by LCx. Discrepant analysis showed two of
these to be false positives (Table 1). Of the 21
samples that were found to be true positives by
LCx, 11 were also positive by PACE2. No samples
that were negative by LCx were positive by
PACE2. Of 75 urine samples that were evaluated
for Ct by LCx, 7 were positive. Discrepant analysis
showed positive to be a false positive and 3 of the
68 negatives were false negatives. One patient was
positive by LCx for Ct in the cervical sample but
negative for Ct by LCx of urine.
Of 203 endocervical samples that were tested for
Ct by culture, 15 were positive. Discrepant analysis
showed 6 of the 188 negatives to be false negatives.
No endocervical samples that were negative by
LCx were positive by any other method. These
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TABLE I. Performance of LCx, PACE2, and culture for detection of Chlamydia trachomatis after discrepant
analysis
True False True False Sensitivity Specificity
Test Source positive positive negative negative (%) (%)
Positive Negative
predictive predictive
value value
(%) ()
LCx Cervix 21 2 182 0 100 98.9
/Cx Urine 6 65 3 66.7 98.5
PACE2 Cervix 0 194 9 52.4 100
Culture Cervix 15 0 182 6 71.4 100
91 100
85.7 95.6
100 95.4
100 96.8
results are summarized in Table where sensitivi-
ties, specificities, and positive and negative predic-
tive values are given. The overall incidence of Ct
detected in this population after discrepant analysis
was 10.2%.
Two endocervical samples that were.positive by
LCx were negative by discrepant analysis. One of
these samples was also positive by urine LCx. It
should be noted, however, that samples were
stored at -20C for approximately 6 months before
discrepant analysis was done, whereas the LCx
package insert indicates that samples should be
stored for no more than 2 months at -20C before
analysis by the standard LCx assay. Samples were,
however, heated to 97C for 15 min prior to storage,
per package insert, and were stored in a frost-free
freezer. Heating should have destroyed most
DNAasc. Because samples were not stored in a
frost-free freezer they did not undergo the freeze-
thaw cycles that might cause sample degradation.
Discrepant analysis involved use of MOMP LCR
that detects a single-copy chromosomal gene,
whereas LCx detects a plasmid that is present in
7-10 copies per chromosome.1 Therefore it is
likely that the LCx assay had greater sensitivity
than the MOMP LCR that was used for confirma-
tion.
DISCUSSION
Based on a review of the literature, this is the only
direct comparison of LCx with the Gen-Probe
PACE2 assay in which conflicting results were re-
solved by discrepant analysis. We found LCx of
endocervical samples to be considerably more sen-
sitive for detection of Ct than the other methods
examined. LCx of cervical samples was 28.6%
more sensitive than culture and PACE2 had a sen-
sitivity of only 52.4%. It should be borne in mind
that the LCx assay is based on the amplification of
nucleic acid and has been shown to be capable of
detecting Ct in urine as long as 12 days after ap-
propriate therapy, leading to the recommendation
that this test not be used for test of cure within 3
weeks of treatment. 11
Others have shown that LCx of first-void urines
(the first 5-20 ml at the beginning of micturation)
had a sensitivity of 93.8 to 100%.8,1z Both first-void
urine collections for LCx8,1z and the midstream
clean-catch specimens that we studied were col-
lected at variable times of the day and were not
necessarily the first void of the day. The high sen-
sitivity of LCx with first-void urines suggested the
possibility that midstream urines collected for rou-
tine urine culture might serve as adequate samples
for LCx which would simplify sample collection.
Interestingly, LCx of midstream clean-catch urines
had a sensitivity of 66.7% which was considerably
less than the sensitivities obtained by others using
first-void urines but was greater than that of
PACE2. Thus the sensitivity of LCx for first-void
urines appeared to be considerably greater than
that for midstream clean-catch urines though the
number of urine samples we examined was rela-
tively small. It appears likely that this difference
was due to loss of the urethral organisms that are
purposefully discarded with the first-void urine
when obtaining a midstream clean-catch urine
sample.
Because the urine samples that were tested by
LCx were selected based on the presence of leu-
kocytes they represent a separate subpopulation.
Chow et al. found leukocyte urine esterase to be
53.1% sensitive and 67.3% specific for Ct compared
to LCx.3 Thus the leukocyte esterase test was
inadequate for use in screening for Ct, but because
of selection based on this test the collection of
urine samples we received would be expected to
be enriched for Ct positive samples. This appears
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to have been the case since 13.8% of patients with
pyuria were positive for Ct whereas 9.3% of pa-
tients without pyuria were positive for Ct. There-
fore it was of interest to compare the urine LCx
results with the results obtained by the other de-
tection methods in this subpopulation. The sensi-
tivity/specificity in this subpopulation was 100/
98.5% for LCx of endocervical samples, 50/100%
for culture, and 33/100% for PACE2. Because of
the smaller number of samples in the urine sub-
population, the differences between the urine sub-
population and the total population are probably
not significant.
Our results indicate that LCx of endocervical
samples had a much higher sensitivity than did the
PACE2 assay or culture (which were the methods
routinely used in our laboratory). Our limited data
does not support routine substitution of midstream
clean-catch urine samples for first-void urines in
the LCx assay.
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